Developer docs
API playgroundTry for free, no card

Search company profiles

Pardes Biosciences

Full company profile

uuid0000mw1

Namestring
Pardes Biosciences
Websiteurl
pardesbio.com
Company typeenum
Private
Founded yearint
2020
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
antiviral therapeutics, biotechnology research, coronavirus treatment, drug development, direct-acting antivirals
Industry1 code
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Antiviral Therapeutics (Biotechnology)
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pardes Biosciences was a clinical-stage biotechnology company developing direct-acting antiviral (DAA) therapeutics for the treatment of coronavirus infections. Its primary focus was on oral protease inhibitors targeting SARS-CoV-2. Following delisting from NASDAQ and the domain being parked, the company appears to no longer be operational.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1PBI-0451 (oral SARS-CoV-2 protease inhibitor program)
CategoryAntiviral small-molecule therapeutics
Description

A clinical-stage, oral direct-acting antiviral therapeutic candidate being developed for the treatment of COVID-19 / SARS-CoV-2 infection, targeting the viral main protease. Intended as a small-molecule treatment for patients with coronavirus infection.

No data
Peers8 records
1Atea Pharmaceuticals
TypeDirect peer
Description

Atea developed AT-527, an oral direct-acting antiviral for COVID-19, making it the closest comparable to Pardes' lead program. Atea similarly struggled as the acute COVID market contracted, illustrating the same single-asset, late-mover risk that materialized for Pardes.

2Shionogi
TypeDirect peer
Description

Shionogi developed ensitrelvir (Xocova), an oral SARS-CoV-2 protease inhibitor approved in Japan, directly comparable to Pardes' oral antiviral approach. Both target the same viral protease mechanism with the same oral, outpatient positioning.

3Cocrystal Pharma
TypeDirect peer
Description

Cocrystal Pharma develops oral broad-spectrum antivirals, including COVID-19 candidates using a structure-based platform. Comparable as a small, publicly traded antiviral developer with a similar capital profile and direct-acting antiviral focus.

4Enanta Pharmaceuticals
TypeDirect peer
Description

Enanta pursued SARS-CoV-2 protease inhibitor candidates as an extension of its hepatitis C virus protease chemistry expertise. Comparable as a small-cap antiviral R&D company with similar mechanism-of-action focus and competitive dynamics.

5Pfizer
TypeBroad incumbent
Description

Pfizer developed and commercialized Paxlovid (nirmatrelvir/ritonavir), which dominated the oral COVID antiviral market and displaced late-arriving entrants like Pardes. Relevant as the dominant incumbent defining the competitive ceiling.

6Merck & Co.
TypeBroad incumbent
Description

Merck developed molnupinavir (Lagevrio), another first-wave oral COVID antiviral that, alongside Paxlovid, captured the bulk of global demand and constrained follow-on programs. Comparable as a broad incumbent shaping the addressable market.

7Vir Biotechnology
TypeEmerging player
Description

Vir pursued COVID-19 therapeutics (initially monoclonal antibodies, later expanding to small-molecule antivirals via collaborations with Alnylam and Brii Biosciences). Comparable as a smaller-cap infectious disease specialist with overlapping pandemic-response themes and a similar trajectory profile.

8RedHill Biopharma
TypeEmerging player
Description

RedHill commercialized opaganib for COVID-19 in select markets and operates as a smaller infectious-disease biotech. Comparable as a sub-scale competitor pursuing COVID antiviral or anti-inflammatory indications.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pardes Biosciences

Antiviral Therapeutics (Biotechnology)pardesbio.com

Pardes Biosciences firmographics

Firmographics
Name
Pardes Biosciences
Website
https://pardesbio.com
Company type
Private
Founded year
2020
Headcount range
11–50 employees
Ownership category
akta.pro rank

Pardes Biosciences industry classification

Industry
Product category
Antiviral Therapeutics (Biotechnology)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Antiviral therapeutics
  • Biotechnology research
  • Coronavirus treatment
  • Drug development
  • Direct-acting antivirals

Where Pardes Biosciences is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Markets served

Pardes Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Pardes Biosciences product offering

Product offering

Core offering

Pardes Biosciences was a clinical-stage biotechnology company developing direct-acting antiviral (DAA) therapeutics for the treatment of coronavirus infections. Its primary focus was on oral protease inhibitors targeting SARS-CoV-2. Following delisting from NASDAQ and the domain being parked, the company appears to no longer be operational.

Differentiator

Problem solved

Functional benefit

Products and services

  • PBI-0451 (oral SARS-CoV-2 protease inhibitor program) A clinical-stage, oral direct-acting antiviral therapeutic candidate being developed for the treatment of COVID-19 / SARS-CoV-2 infection, targeting the viral main protease. Intended as a small-molecule treatment for patients with coronavirus infection.

Companies that use Pardes Biosciences

Customer profile

Ideal customer profiles1 record

Pardes Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Pardes Biosciences competitors and assessment

Company assessment

Direct peers

  • Atea Pharmaceuticals: Atea developed AT-527, an oral direct-acting antiviral for COVID-19, making it the closest comparable to Pardes' lead program. Atea similarly struggled as the acute COVID market contracted, illustrating the same single-asset, late-mover risk that materialized for Pardes.
  • Shionogi: Shionogi developed ensitrelvir (Xocova), an oral SARS-CoV-2 protease inhibitor approved in Japan, directly comparable to Pardes' oral antiviral approach. Both target the same viral protease mechanism with the same oral, outpatient positioning.
  • Cocrystal Pharma: Cocrystal Pharma develops oral broad-spectrum antivirals, including COVID-19 candidates using a structure-based platform. Comparable as a small, publicly traded antiviral developer with a similar capital profile and direct-acting antiviral focus.
  • Enanta Pharmaceuticals: Enanta pursued SARS-CoV-2 protease inhibitor candidates as an extension of its hepatitis C virus protease chemistry expertise. Comparable as a small-cap antiviral R&D company with similar mechanism-of-action focus and competitive dynamics.

Broad incumbents

  • Pfizer: Pfizer developed and commercialized Paxlovid (nirmatrelvir/ritonavir), which dominated the oral COVID antiviral market and displaced late-arriving entrants like Pardes. Relevant as the dominant incumbent defining the competitive ceiling.
  • Merck & Co. Merck developed molnupinavir (Lagevrio), another first-wave oral COVID antiviral that, alongside Paxlovid, captured the bulk of global demand and constrained follow-on programs. Comparable as a broad incumbent shaping the addressable market.

Emerging players

  • Vir Biotechnology: Vir pursued COVID-19 therapeutics (initially monoclonal antibodies, later expanding to small-molecule antivirals via collaborations with Alnylam and Brii Biosciences). Comparable as a smaller-cap infectious disease specialist with overlapping pandemic-response themes and a similar trajectory profile.
  • RedHill Biopharma: RedHill commercialized opaganib for COVID-19 in select markets and operates as a smaller infectious-disease biotech. Comparable as a sub-scale competitor pursuing COVID antiviral or anti-inflammatory indications.

Market position

Customer concentration

Pardes Biosciences social profiles

Digital presence

Pardes Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pardes Biosciences leadership team

Management profile

Number of profiles

Profiles2 records

Pardes Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pardes Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pardes Biosciences

What does Pardes Biosciences do?

Pardes Biosciences was a clinical-stage biotechnology company developing direct-acting antiviral (DAA) therapeutics for the treatment of coronavirus infections. Its primary focus was on oral protease inhibitors targeting SARS-CoV-2. Following delisting from NASDAQ and the domain being parked, the company appears to no longer be operational.

When was Pardes Biosciences founded?

Pardes Biosciences was founded in 2020. It employs 11 to 50 people.

Where is Pardes Biosciences based?

Pardes Biosciences is headquartered in Carlsbad, United States, in the North America region.

Who are Pardes Biosciences's main competitors?

Direct peers on record are Atea Pharmaceuticals, Shionogi, Cocrystal Pharma and Enanta Pharmaceuticals. Broad incumbents are Pfizer and Merck & Co.. Emerging players are Vir Biotechnology and RedHill Biopharma.

Does Pardes Biosciences have an API?

No public API is recorded for Pardes Biosciences.

What industry is Pardes Biosciences in?

Pardes Biosciences's product category is Antiviral Therapeutics (Biotechnology). Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerMediPacific, Inc. completed the acquisition of Pardes Biosciences, Inc. from a group of shareholders.MediPacific, Inc. completed the acquisition of Pardes Biosciences, Inc. from a group of shareholders on August 31, 2023, for approximately $130 million. The transaction involved a tender offer where MediPacific acquired all outstanding shares at $2.13 per share in cash, along with contingent value rights associated with Pardes's COVID-19 antiviral portfolio. Following the closing, Pardes became a wholly owned subsidiary of MediPacific and was delisted from the Nasdaq stock exchange.Business Wire BlogMediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesMediPacific Sub, Inc., an affiliate of Foresite Capital, has commenced a tender offer to acquire all outstanding shares of Pardes Biosciences for $2.13 per share plus a contingent value right. As of August 25, 2023, approximately 13.2% of Pardes' common stock had been validly tendered, with the transaction expected to close in the third quarter of 2023 subject to customary conditions.GlobeNewswirePardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsPardes Biosciences entered a definitive merger agreement with MediPacific, Inc. to be acquired for $2.02–$2.19 per share in cash plus contingent value rights. The tender offer is expected to close in the third quarter of 2023, subject to conditions including a $125 million net cash requirement.BenzingaWhy Pardes Biosciences Shares Are Rising MondayMediPacific has agreed to acquire Pardes Biosciences Inc for $2.02 to $2.19 per share in cash, plus contingent value rights tied to its COVID-19 antiviral portfolio. The acquisition will proceed via a tender offer by July 28, expected to close in the third quarter. Following the announcement, Pardes Biosciences shares surged 15.1% to $2.13.GlobeNewswirePardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsPardes Biosciences announced a definitive merger agreement to be acquired by MediPacific for between $2.02 and $2.19 per share in cash, plus contingent value rights tied to its COVID-19 antiviral portfolio. The deal was unanimously recommended by Pardes' independent Special Committee as being in the best interests of unaffiliated stockholders. The transaction is expected to close in the third quarter of 2023.BenzingaPardes Biosciences Looks For Alternatives After Failed COVID-19 StudyPardes Biosciences reported that its Phase 2 clinical trial for pomotrelvir failed to meet the primary endpoint for treating mild-to-moderate COVID-19 in vaccinated adults. Consequently, the company has suspended further development of the drug and is exploring strategic alternatives. The firm stated it has sufficient cash reserves to fund operations for the next twelve months.PR NewswireRM LAW Announces Investigation of Pardes Biosciences, Inc.RM LAW, P.C. announced on January 30, 2023, that it is investigating potential claims against the board of directors of Pardes Biosciences, Inc. regarding possible violations of federal securities laws. The investigation focuses on the company's operations as a special purpose acquisition company (SPAC). Investors holding shares are encouraged to contact the law firm for more information.BenzingaThe Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros GetsThe biotech sector saw multiple developments over the last 24 hours, with Mersana Therapeutics announcing a research collaboration with Johnson & Johnson's Janssen unit worth over $1 billion in potential milestone payments for novel antibody-drug conjugate development. FDA regulatory activity included Syros Pharmaceuticals receiving orphan drug designation for tamibarotene in myelodysplastic syndrome and Pardes Biosciences gaining clearance to begin Phase 1 studies of its oral antiviral PBI-0451. Quarterly earnings reports showed mixed results, with Valneva reporting 216% revenue growth while Roche warned of slowing growth and Arrowhead posted a wider-than-expected loss per share.GlobeNewswirePardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19Pardes Biosciences completed its SPAC merger with FS Development Corp. II on December 23, 2021, and will trade on Nasdaq under PRDS. The transaction generated approximately $274 million in gross proceeds, including $199 million from the trust and $75 million from PIPE financing. The company's lead oral antiviral PBI-0451 is in Phase I trial, with top-line results expected in Q1 2022.BenzingaGilead, Foresite Take Pardes Biosciences Public In $250M SPAC Deal - Gilead Sciences (NASDAQ:GILD)Pardes Biosciences Inc, an early-stage biopharmaceutical company founded in 2020 by former Gilead executive Uri Lopatin, is going public through a SPAC merger with FS Development Corp. II, a Foresite Capital-sponsored blank-check company. The deal values the transaction at approximately $250 million, combining $175 million from the SPAC with an additional $75 million in private investment from Gilead Sciences, RA Capital Management, and Frazier Life Sciences. The company plans to initiate clinical trials for its oral antiviral drug candidate PBI-0451, designed to treat and prevent COVID-19, later this year.